Pharmacometabolomics of Respiratory Phenotypic Response to Dexamethasone in Preterm Infants at Risk for Bronchopulmonary Dysplasia
A prospective cohort study was performed in preterm infants less than 32 weeks gestation at birth who were treated with dexamethasone for developing or established bronchopulmonary dysplasia (BPD). Respiratory phenotype (Respiratory Severity Score (RSS)), serum, and urine metabolomics were assessed...
Saved in:
Main Authors: | Tamorah Lewis (Author), Prabhakar Chalise (Author), Cheri Gauldin (Author), William Truog (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2019-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacometabolomics Profiling of Preterm Infants Validates Patterns of Metabolism Associated With Response to Dexamethasone Treatment for Bronchopulmonary Dysplasia
by: Bradley Stockard, et al.
Published: (2022) -
Delayed Dexamethasone Therapy and Neurodevelopmental Outcomes in Preterm Infants with Bronchopulmonary Dysplasia
by: Gina Lim, et al.
Published: (2015) -
Pharmacoepidemiology of Drug Exposure in Intubated and Non-Intubated Preterm Infants With Severe Bronchopulmonary Dysplasia
by: T. Lewis, et al.
Published: (2021) -
Respiratory Tract Microecology and Bronchopulmonary Dysplasia in Preterm Infants
by: Tong Sun, et al.
Published: (2021) -
Predictors of Developmental and Respiratory Outcomes Among Preterm Infants With Bronchopulmonary Dysplasia
by: Iris Morag, et al.
Published: (2021)